↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Gathmann I) "

Search: WFRF:(Gathmann I)

Result 1-3 of 3

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	O'Brien, SG, et al. (author) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia 2003 In: The New England journal of medicine. - 1533-4406. ; 348, s. 994- Journal article (peer-reviewed)
2.	Gathmann, B, et al. (author) Clinical picture and treatment of 2212 patients with common variable immunodeficiency 2014 In: The Journal of allergy and clinical immunology. - : Elsevier BV. - 1097-6825 .- 0091-6749. ; 134:1, s. 116- Journal article (peer-reviewed)
3.	Hochhaus, A, et al. (author) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. 2009 In: Leukemia. - : Springer Science and Business Media LLC. - 1476-5551 .- 0887-6924. ; 23:6, s. 1054-61 Journal article (peer-reviewed)abstract Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously untreated CML-CP patients were randomized to imatinib (n=553) or interferon-alpha (IFN) plus cytarabine (n=553). This 6-year update focuses on patients randomized to receive imatinib as first-line therapy for newly diagnosed CML-CP. During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC). The toxicity profile was unchanged. The cumulative best complete cytogenetic response (CCyR) rate was 82%; 63% of all patients randomized to receive imatinib and still on study treatment showed CCyR at last assessment. The estimated event-free survival at 6 years was 83%, and the estimated rate of freedom from progression to AP and BC was 93%. The estimated overall survival was 88% -- or 95% when only CML-related deaths were considered. This 6-year update of IRIS underscores the efficacy and safety of imatinib as first-line therapy for patients with CML.

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-3 of 3

Refine your search

Type of publication: journal article (3)

Type of content: peer-reviewed (3)

Author/Editor: Hochhaus, A (2); Guilhot, F (2); Turesson, I (1); Limentani, S. (1); Brown, R. (1); Jones, A. (1); show more...; Stone, R. (1); Collins, R (1); Ciznar, P (1); Kindle, G (1); Sediva, A (1); Borte, S (1); Gerard, L. (1); Glass, J (1); Witte, T (1); Shea, T. (1); Wadenvik, Hans, 1955 (1); Foroni, L (1); Cooper, S (1); Hughes, T (1); Herzig, R (1); Powell, B (1); Dakhil, S. (1); Buyse, M (1); Mahlaoui, N (1); Paul, C (1); Thompson, K (1); Wade, J. (1); Forrest, D (1); Moore, J (1); Gedde-Dahl, T. (1); Bienemann, K (1); Martinelli, G (1); Bhatia, R (1); Cervantes, F (1); Larson, RA (1); Michallet, M (1); Simonsson, B. (1); Meyts, I (1); Arthur, C (1); Soler-Palacin, P (1); Green, AR (1); Nobile, F. (1); Kovacs, M (1); Facon, T (1); Hart, R (1); Gratwohl, A (1); Blaise, D. (1); Bashey, A (1); Smith, G (1); show less...

University: Karolinska Institutet (2); University of Gothenburg (1); Uppsala University (1)

Language: English (3)

Research subject (UKÄ/SCB): Medical and Health Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view